Fig. 5
From: Efficacy of galcanezumab in migraine central sensitization
The mean MIDAS score changes. The mean total MIDAS score improved significantly from 48.6 at baseline to 23.1 at 3 months (p < 0.001 vs. baseline) and 22.8 at 6 months (p < 0.001 vs. baseline). Each of the MIDAS items also showed significant improvement in comparison to baseline from 3 to 6 months. MIDAS: Migraine Disability Assessment.
